Article info

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

Authors

  1. Correspondence to Dr Xiaohua Wu, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; wu.xh.fudan{at}protonmail.com
View Full Text

Citation

Xia L, Wang J, Wang C, et al
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

Publication history

  • Received June 4, 2023
  • Accepted September 28, 2023
  • First published October 24, 2023.
Online issue publication 
December 04, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.